Breast MRI using a high-relaxivity contrast agent: An overview

American Journal of Roentgenology

Volumn 196, Issue 4, 2011, Pages 942-955

  Carbonaro, Luca A ^a   Pediconi, Federica ^b   Verardi, Nicola ^c   Trimboli, Rubina M ^c   Calabrese, Massimo ^d   Sardanelli, Francesco ^a,c  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; Contrast agent; Gadobenate dimeglumine; High relaxivity; MRI

Indexed keywords

CHOLINE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

BLOOD VESSEL; BREAST; BREAST CANCER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG STABILITY; FALSE POSITIVE RESULT; HUMAN; INJECTION SITE PAIN; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION FIELD; RELAXATION TIME; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; BREAST TUMOR; CHEMISTRY; FEMALE; METHODOLOGY;

BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; SENSITIVITY AND SPECIFICITY;

EID: 79957792385     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4974     Document Type: Review

References (54)

1. Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10:199-204 (Pubitemid 16113395)
2. Heywang-Kobrunner SH, Beck R. Contrast-enhanced MRI of the breast, 2nd ed. Berlin, Germany: Springer-Verlag, 1995
3. Sardanelli F, Iozzelli A, Fausto A. Contrast agents and temporal resolution in breast MR imaging. J Exp Clin Cancer Res 2002; 21:69-75 (Pubitemid 36114238)
4. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008; 66:160-167
5. Kuhl CK. Current status of breast MR imaging. Part 1. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244:672-691
6. Sardanelli F, Giuseppetti GM, Canavese G, et al. Indications for breast magnetic resonance imaging: consensus document "Attualità in senologia," Florence 2007. Radiol Med 2008; 113:1085-1095
7. Tweedle MF, Wedeking P, Krishan K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995; 30:372-380
8. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003; 14:426-435 (Pubitemid 37521732)
9. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40:715-724 (Pubitemid 41546838)
10. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006; 41:222-228 (Pubitemid 44406182)
11. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999; 6:282-291 (Pubitemid 32673373)
12. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997; 32:780-796 (Pubitemid 28053510)
13. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9:713-725 (Pubitemid 36749220)
14. Banci L, Bertini I, Luchinat C. Nuclear and electron relaxation. Weinheim, Germany: VCH Verlagsgesellschaft, 1991
15. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR 2003; 181:663-676 (Pubitemid 37021833)
16. Hylton NM. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast. AJR 2003; 181:677-678 (Pubitemid 37021834)
17. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology 2005; 237:45-56 (Pubitemid 41346145)
18. Pediconi F, Catalano C, Padula S, et al. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine. AJR 2008; 191:1339-1346
19. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89 [Erratum in CA Cancer J Clin 2007; 57:185]
20. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008; 26:3248-3258
21. Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010; 46:1296-1316
22. Sardanelli F. Overview of the role of pre-operative breast MRI in the absence of evidence on patient outcomes. Breast 2010; 19:3-6
23. Solin LJ. Counterview: pre-operative breast MRI (magnetic resonance imaging) is not recommended for all patients with newly diagnosed breast cancer. Breast 2010; 19:7-9
24. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010; 375:563-571
25. Morris EA. Should we dispense with preoperative breast MRI? Lancet 2010; 375:528-530
26. Pediconi F, Catalano C, Padula S, et al. Contrast-enhanced magnetic resonance mammography: does it affect surgical decision-making in patients with breast cancer? Breast Cancer Res Treat 2007; 106:65-74 (Pubitemid 47498089)
27. Pediconi F, Catalano C, Roselli A, et al. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions. Radiology 2007; 243:670-680 (Pubitemid 46799419)
28. Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003; 226:773-778 (Pubitemid 36259154)
29. Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR 2003; 180:333-341 (Pubitemid 36135009)
30. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303 (Pubitemid 46513295)
31. Schell AM, Rosenkranz K, Lewis PJ. Role of breast MRI in the preoperative evaluation of patients with newly diagnosed breast cancer. AJR 2009; 192:1438-1444
32. Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 2009; 27:5640-5649
33. Sardanelli F, Fausto A, Esseridou A, Di Leo G, Kirchin MA. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol 2008; 43:236-242 (Pubitemid 351416767)
34. Carbonaro LA, Verardi N, Di Leo G, Sardanelli F. Handling a high relaxivity contrast material for dynamic breast MR imaging using higher thresholds for the initial enhancement. Invest Radiol 2010; 45:114-120
35. Sardanelli F, Iozzelli A, Fausto A, Carriero A, Kirchin MA. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology 2005; 235:791-797 (Pubitemid 40695871)
36. Mahfouz AE, Sherif H, Saad A, et al. Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity? Eur Radiol 2001; 11:965-969 (Pubitemid 32755559)
37. Carriero A, Ambrossini R, Mattei PA, Angelucci D, Bonomo L. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. J Exp Clin Cancer Res 2002; 21:83-87 (Pubitemid 36114240)
38. Schmitz AC, Peters NH, Veldhuis WB, et al. Contrast-enhanced 3.0-T breast MRI for characterization of breast lesions: increased specificity by using vascular maps. Eur Radiol 2008; 18:355-364 (Pubitemid 351234057)
39. Calabrese M, Brizzi D, Carbonaro L, Chiaramondia M, Kirchin MA, Sardanelli F. Contrast-enhanced breast MR imaging of claustrophobic or oversized patients using an open low-field magnet. Radiol Med 2009; 114:267-285
40. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002; 94:1197-1203 (Pubitemid 34993869)
41. Bartella L, Thakur SB, Morris EA, et al. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245:80-87 (Pubitemid 47417790)
42. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR 2009; 192:1608-1617
43. Smith JK, Kwock L, Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR 2000; 21:1084-1089 (Pubitemid 30390548)
44. Lenkinski RE, Wang X, Elian M, Goldberg SN. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med 2009; 61:1286-1292
45. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799-806
46. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108 [Erratum in Nephrol Dial Transplant 2006; 21:1745]
47. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66:230-234
48. van der Molen AJ. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. J Med Imaging Radiat Oncol 2008; 52:339-350
49. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR 2008; 190:736-741 (Pubitemid 351304519)
50. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41:213-221 [Erratum in Invest Radiol 2006; 41:859]
51. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 2005; 236:789-800 (Pubitemid 41170839)
52. Kuhl CK, Jost P, Morakkabati N, Zivanovic O, Schild HH, Gieseke J. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology 2006; 239: 666-676 (Pubitemid 43830601)
53. Kuhl CK, Breast MR. Imaging at 3T. Magn Reson Imaging Clin N Am 2007; 15:315-320
54. Multihance Versus Magnevist in Breast MRI (DETECT). clinicaltrials.gov/ ct2/show/NCT00486473. Updated July 14, 2010. Accessed July 27, 2010